Larimar Therapeutics (LRMR) Consolidated Net Income: 2014-2020
Historic Consolidated Net Income for Larimar Therapeutics (LRMR) over the last 6 years, with Mar 2020 value amounting to -$3.6 million.
- Larimar Therapeutics' Consolidated Net Income rose 72.55% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 38.50%. This contributed to the annual value of -$45.4 million for FY2019, which is 25.68% up from last year.
- According to the latest figures from Q1 2020, Larimar Therapeutics' Consolidated Net Income is -$3.6 million, which was up 50.66% from -$7.3 million recorded in Q4 2019.
- Larimar Therapeutics' 5-year Consolidated Net Income high stood at -$3.6 million for Q1 2020, and its period low was -$17.8 million during Q1 2016.
- Its 3-year average for Consolidated Net Income is -$12.2 million, with a median of -$13.1 million in 2019.
- As far as peak fluctuations go, Larimar Therapeutics' Consolidated Net Income tumbled by 32.76% in 2016, and later spiked by 72.55% in 2020.
- Larimar Therapeutics' Consolidated Net Income (Quarterly) stood at -$10.3 million in 2016, then declined by 26.76% to -$13.1 million in 2017, then declined by 10.72% to -$14.5 million in 2018, then surged by 49.65% to -$7.3 million in 2019, then spiked by 72.55% to -$3.6 million in 2020.
- Its Consolidated Net Income stands at -$3.6 million for Q1 2020, versus -$7.3 million for Q4 2019 and -$12.9 million for Q3 2019.